ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
AAS induced liver injury
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 191301" data-attributes="member: 13851"><p><strong>Androgenic anabolic steroid-induced liver injury:</strong> <span style="color: rgb(184, 49, 47)"><strong>two case reports assessed for causality by the updated Roussel Uclaf Causality Assessment Method </strong></span><span style="color: rgb(0, 0, 0)"><strong>(RUCAM)</strong></span><span style="color: rgb(184, 49, 47)"><strong> score and a comprehensive review of the literature </strong></span></p><p><span style="color: rgb(44, 130, 201)">Robin Daniel Abeles, Matthew Foxton, Shahid Khan, Robert Goldin, Belinda Smith, Mark R Thursz, Suman Verma</span></p><p></p><p></p><p></p><p></p><p></p><p><strong>ABSTRACT </strong></p><p><strong></strong></p><p><strong>Background</strong> <span style="color: rgb(184, 49, 47)"><em>Anabolic-androgenic steroids (AAS) usage is widespread and increasing.</em></span> <em><span style="color: rgb(44, 130, 201)"><u>AAS drug-induced liver injury (DILI) is recognized but its clinical course and management are poorly described</u>. We report 2 cases of AAS DILI with associated renal dysfunction, managed successfully with oral corticosteroids. </span></em></p><p></p><p><strong>Methods</strong> <em><span style="color: rgb(184, 49, 47)">A comprehensive review identified 50 further cases to characterize the clinical and biochemical course. </span></em><span style="color: rgb(44, 130, 201)">Causality grading was calculated using the updated Roussel Uclaf Causality Assessment Method (RUCAM) score. Data are presented as median values.</span></p><p></p><p><strong>Results</strong> <span style="color: rgb(184, 49, 47)"><em>The most common AAS taken as methandrostenolone. </em></span><span style="color: rgb(44, 130, 201)"><em>Patients commonly present with jaundice and pruritus but may exhibit other constitutional symptoms. </em></span><span style="color: rgb(184, 49, 47)"><em>Patients presented 56 days after starting, and bilirubin peaked 28 days after stopping, AAS. Causality assessment was ‘unlikely’ in 1 (2%), ‘possible’ in 31 (60%), and ‘probable’ in 20 (38%).</em></span> <em><span style="color: rgb(44, 130, 201)"><u>Peak values were: bilirubin 705 μmol/L, alanine transaminase 125U/L, aspartate transaminase 71U/L, alkaline phosphatase 262U/L, gamma-glutamyl transferase 52U/L, international normalized ratio 1.1. Liver biopsies showed ‘bland’ canalicular cholestasis. 43% of patients developed kidney injury (peak creatinine 225 μmol/L)</u>. Therapies included antipruritics, ursodeoxycholic acid, and corticosteroids. No patients died or required liver transplantation. </span></em></p><p></p><p><strong>Conclusions </strong><em><span style="color: rgb(184, 49, 47)">Physicians are likely to encounter AAS DILI. </span></em><span style="color: rgb(44, 130, 201)"><em>Causality assessment using the updated RUCAM should be performed but defining indications and proving efficacy for therapies remains challenging.</em></span></p><p></p><p></p><p></p><p></p><p></p><p><strong>INTRODUCTION </strong></p><p></p><p><em><span style="color: rgb(184, 49, 47)">Anabolic-androgenic steroid (AAS) use for performance-enhancing and cosmetic reasons is rising with a lifetime prevalence of 3%–4% in Europe and the USA.1 </span></em></p><p><em><span style="color: rgb(184, 49, 47)"></span></em></p><p><em><span style="color: rgb(184, 49, 47)">Although the potential for cholestatic AAS drug-induced liver injury (DILI) has been recognized for many years,2 the clinical course and optimal management of these patients remains unclear.</span></em> <em><span style="color: rgb(44, 130, 201)"><u><strong>We present two cases of AAS DILI and perform the most comprehensive literature review to date of the topic</strong></u>. </span></em></p><p></p><p></p><p></p><p></p><p></p><p></p><p><strong><em><span style="color: rgb(184, 49, 47)">In conclusion, AAS use is widespread and rising and all physicians are likely to encounter patients with AAS DILI. </span></em></strong><em><strong><span style="color: rgb(44, 130, 201)">The updated RUCAM score and causality assessment should be calculated on all patients where DILI is suspected, although conclusively identifying AAS as the culprit agent can be challenging due to the frequent concurrent consumption of bodybuilding supplements and the clinical desire to give treatment. </span></strong></em><span style="color: rgb(184, 49, 47)"><em><strong><u>Thankfully, the prognosis is excellent and that, although there is a paucity of high-quality data to guide management, it is reasonable to consider antihistamines or UDCA in symptomatic patients or corticosteroids in those with extreme elevations of bilirubin associated with elevated Cr</u>.</strong></em></span></p></blockquote><p></p>
[QUOTE="madman, post: 191301, member: 13851"] [B]Androgenic anabolic steroid-induced liver injury:[/B] [COLOR=rgb(184, 49, 47)][B]two case reports assessed for causality by the updated Roussel Uclaf Causality Assessment Method [/B][/COLOR][COLOR=rgb(0, 0, 0)][B](RUCAM)[/B][/COLOR][COLOR=rgb(184, 49, 47)][B] score and a comprehensive review of the literature [/B][/COLOR] [COLOR=rgb(44, 130, 201)]Robin Daniel Abeles, Matthew Foxton, Shahid Khan, Robert Goldin, Belinda Smith, Mark R Thursz, Suman Verma[/COLOR] [B]ABSTRACT Background[/B] [COLOR=rgb(184, 49, 47)][I]Anabolic-androgenic steroids (AAS) usage is widespread and increasing.[/I][/COLOR] [I][COLOR=rgb(44, 130, 201)][U]AAS drug-induced liver injury (DILI) is recognized but its clinical course and management are poorly described[/U]. We report 2 cases of AAS DILI with associated renal dysfunction, managed successfully with oral corticosteroids. [/COLOR][/I] [B]Methods[/B] [I][COLOR=rgb(184, 49, 47)]A comprehensive review identified 50 further cases to characterize the clinical and biochemical course. [/COLOR][/I][COLOR=rgb(44, 130, 201)]Causality grading was calculated using the updated Roussel Uclaf Causality Assessment Method (RUCAM) score. Data are presented as median values.[/COLOR] [B]Results[/B] [COLOR=rgb(184, 49, 47)][I]The most common AAS taken as methandrostenolone. [/I][/COLOR][COLOR=rgb(44, 130, 201)][I]Patients commonly present with jaundice and pruritus but may exhibit other constitutional symptoms. [/I][/COLOR][COLOR=rgb(184, 49, 47)][I]Patients presented 56 days after starting, and bilirubin peaked 28 days after stopping, AAS. Causality assessment was ‘unlikely’ in 1 (2%), ‘possible’ in 31 (60%), and ‘probable’ in 20 (38%).[/I][/COLOR] [I][COLOR=rgb(44, 130, 201)][U]Peak values were: bilirubin 705 μmol/L, alanine transaminase 125U/L, aspartate transaminase 71U/L, alkaline phosphatase 262U/L, gamma-glutamyl transferase 52U/L, international normalized ratio 1.1. Liver biopsies showed ‘bland’ canalicular cholestasis. 43% of patients developed kidney injury (peak creatinine 225 μmol/L)[/U]. Therapies included antipruritics, ursodeoxycholic acid, and corticosteroids. No patients died or required liver transplantation. [/COLOR][/I] [B]Conclusions [/B][I][COLOR=rgb(184, 49, 47)]Physicians are likely to encounter AAS DILI. [/COLOR][/I][COLOR=rgb(44, 130, 201)][I]Causality assessment using the updated RUCAM should be performed but defining indications and proving efficacy for therapies remains challenging.[/I][/COLOR] [B]INTRODUCTION [/B] [I][COLOR=rgb(184, 49, 47)]Anabolic-androgenic steroid (AAS) use for performance-enhancing and cosmetic reasons is rising with a lifetime prevalence of 3%–4% in Europe and the USA.1 Although the potential for cholestatic AAS drug-induced liver injury (DILI) has been recognized for many years,2 the clinical course and optimal management of these patients remains unclear.[/COLOR][/I] [I][COLOR=rgb(44, 130, 201)][U][B]We present two cases of AAS DILI and perform the most comprehensive literature review to date of the topic[/B][/U]. [/COLOR][/I] [B][I][COLOR=rgb(184, 49, 47)]In conclusion, AAS use is widespread and rising and all physicians are likely to encounter patients with AAS DILI. [/COLOR][/I][/B][I][B][COLOR=rgb(44, 130, 201)]The updated RUCAM score and causality assessment should be calculated on all patients where DILI is suspected, although conclusively identifying AAS as the culprit agent can be challenging due to the frequent concurrent consumption of bodybuilding supplements and the clinical desire to give treatment. [/COLOR][/B][/I][COLOR=rgb(184, 49, 47)][I][B][U]Thankfully, the prognosis is excellent and that, although there is a paucity of high-quality data to guide management, it is reasonable to consider antihistamines or UDCA in symptomatic patients or corticosteroids in those with extreme elevations of bilirubin associated with elevated Cr[/U].[/B][/I][/COLOR] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
AAS induced liver injury
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top